Do we need pharmacological therapy for atrial fibrillation in the ablation era?

Journal of Interventional Cardiac Electrophysiology

Volumn 17, Issue 3, 2006, Pages 189-194

  Lévy, Samuel ^a  

^a HÔPITAL NORD   (France)

Author keywords

Ablation; Atrial fibrillation; Pharmacological therapy

Indexed keywords

2' (4 METHOXYPHENYLACETAMIDOMETHYL) N [2 (3 PYRIDYL)ETHYL] 2 BIPHENYLCARBOXAMIDE; AMBASILIDE; AMIODARONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; AZD 7009; AZIMILIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CIBENZOLINE; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; DOFETILIDE; DRONEDARONE; ERSENTILIDE; FLECAINIDE; GAP JUNCTION PROTEIN; HEPARIN; IBUTILIDE; ION CHANNEL; IRBESARTAN; PROCAINAMIDE; PROPAFENONE; QUINIDINE; RDS 1235; SOTALOL; TEDISAMIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; XEN D0101;

CARDIOVERSION; CATHETER ABLATION; COMBINATION CHEMOTHERAPY; DIAGNOSTIC IMAGING; DRUG SAFETY; GAP JUNCTION; HEART ATRIUM FIBRILLATION; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; LABORATORY; LIVER DISEASE; LUNG DISEASE; MONOTHERAPY; NEUROLOGIC DISEASE; PHYSICIAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QT PROLONGATION; RECURRENT DISEASE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SINUS RHYTHM; SKIN DISEASE; SURVIVAL; TORSADE DES POINTES;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CATHETER ABLATION; COMBINED MODALITY THERAPY; ELECTRIC COUNTERSHOCK; HEART RATE; HUMANS; RECURRENCE; RENIN-ANGIOTENSIN SYSTEM; WORLD HEALTH;

EID: 34247235704     PISSN: 1383875X     EISSN: 15728595     Source Type: Journal    
DOI: 10.1007/s10840-006-9075-8     Document Type: Review

References (41)

1. Lévy, S., Breithardt, G., Campbell, R. W., Camm, A. J., Daubert, J. C., Allessie, M., et al. (1998). Atrial fibrillation: Current knowledge and recommendations for management. Working Group on Arrhythmias of the European Society of Cardiology. European Heart Journal, 19, 1294-1320.
2. Lévy, S., Camm, A. J., Saksena, S., Aliot, E., Breithardt, G., Crijns, H., et al. (2003). International consensus on nomenclature and classification of atrial fibrillation. Europace, 5, 119-122.
3. Fuster, V., Ryden, L., Asinger, R. W., Cannom, D. S., Crijns, H. J., Frye, R. L., et al. (2001). ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology for Practice Guidelines and Policy Conferences. European Heart Journal, 22, 1852-1923.
4. Wyse, D. G., for the AFFIRM Investigators (2002). Survival in patients presenting with atrial fibrillation: The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. New England Journal of Medicine, 347, 1825-1833.
5. Van Gelder, I. C., Hagens, V. E., Bosker, H. A., Kingma, J. H., Kamp, O., Kingma, T., et al. (2002). A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. New England Journal of Medicine, 347, 1834-1840.
6. Haissaguerre, M., Jais, P., Shah, D. C., Takahashi, A., Hocini, M., Quiniou, G., et al. (1998). Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. New England Journal of Medicine, 339, 659-666.
7. Oral, H., Chugh, A., Good, E., Sankaran, S., Reich, S. S., Igic, P., et al. (2006). A tailored approach to catheter ablation of paroxysmal atrial fibrillation. Circulation, 18(113), 1824-1831.
8. Karch, M. R., Zrenner, B., Deisenhofer, I., Schreieck, J., Ndrepepa, G., Dong, J., et al. (2005). Freedom from atrial tachyarrhythmias after catheter ablation of atrial fibrillation: A randomized comparison between 2 current ablation strategies. Circulation, 7(111), 2875-2880.
9. Pappone, C., & Santinelli, V. (2005). Atrial fibrillation ablation: State of the art. American Journal of Cardiology, 96(12A), 59L-64L.
10. Wood, M. A., & Ellenbogen, K. A. (2006). Catheter ablation of chronic atrial fibrillation - The gap between promise and practice. New England Journal of Medicine, 354, 967-969.
11. Lévy, S., Maarek, M., Coumel, P., Guize, L., Lekieffre, J., Medvedowsky, J. L., et al. (1999). Characterization of different subsets of atrial fibrillation in general practice in France: The Alfa study. Circulation, 99, 3028-3035.
12. Vaughan Williams, E. M. (1984). A classification of antiarrhythmic actions reassessed after a decade of new drugs. Journal of Clinical Pharmacology, 24, 129-147.
13. Steinberg, J. S., Sadaniantz, A., Kron, J., Krahn, A., Denny, D. M., Daubert, J., et al. (2004). Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation, 27(109), 1973-1980.
14. Patten, M., Maas, R., Bauer, P., Lüderitz, B., Sonntag, F., Dluzniewski, M., et al. (2004). Suppression of paroxysmal atrial tachyarrhythmias - Results of the SOPAT trial. European Heart Journal, 25, 1395-1404.
15. Roy, D., Talajic, M., Dorian, P., Connolly, S., Eisenberg, M. J., Green, M., et al. (2000). Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. New England Journal of Medicine, 342, 913-920.
16. Singh, B. N., Singh, S. N., Reda, D. J., Tang, X. C., Lopez, B., Harris, C. L., et al. (2005). Amiodarone versus sotalol for atrial fibrillation. New England Journal of Medicine, 352, 1861.
17. Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., et al. (2006). ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines. Journal of the American College of Cardiology, 48, e149-e246 (Aug 15).
18. Santini, M., De Ferrari, G. M., Pandozi, C., et al. (2004). Atrial fibrillation requiring urgent medical care. Approach and outcome in the various departments of admission. Data from atrial fibrillation/flutter Italian Registry Trial (FIRE). Italian Heart Journal, 5, 205-213.
19. Capucci, A., Tizziano, L., Boriani, G., Trisolino, G., Binetti, N., Cavazza, M., et al. (1992). Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. American Journal of Cardiology, 70, 69-72.
20. Alboni, P., Botto, G. L., Baldi, N., Luzi, M., Russo, V., Gianfranchi, L., et al. (2004). Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. New England Journal of Medicine, 351, 2384-2391.
21. Stambler, B. S., Wood, M. A., Ellenbogen, K. A., Perry, K. T., Wakefield, L. K., & VanderLugt, J. T. (1996). Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation, 1(94), 1613-1621.
22. Pratt, C. M., Singh, S. N., Al-Khalidi, H. R., Brum, J. M., Holroyde, M. J., Marcello, S. R., et al. (2004). The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: Results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial. Journal of the American College of Cardiology, 43, 1211-1216.
23. Pritchett, E. L., Kowey, P., Connolly, S., Page, R. L., Kerr, C., & Wilkinson, W. E. (2006). Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm. American Heart Journal, 151, 1043-1049.
24. Hohnloser, S. H., Dorian, P., Straub, M., Beckmann, K., & Kowey, P. (2004). Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter. Journal of the American College of Cardiology, 44, 99-104.
25. Touboul, P., Brugada, J., Capucci, A., Crijns, H. J., Edvardsson, N., Hohnloser, S. H. (2003). Dronedarone for prevention of atrial fibrillation: A dose-ranging study. European Heart Journal, 24, 1481-1487.
26. Kathofer, S., Thomas, D., & Karle, C. A. (2005). The novel antiarrhythmic drug dronedarone: Comparison with amiodarone. Cardiovascular Drug Reviews, 23, 217-230.
27. Levy, S. (2006). Drug insight: Angiotensin-converting-enzyme inhibitors and atrial fibrillation - Indications and contraindications. Nat Clin Pract Cardiovascular Med, 3(4), 220-225.
28. Klein, H. U., & Goette, A. (2003). Blockade of atrial angiotensin II type 1 receptors: A novel antiarrhythmic strategy to prevent atrial fibrillation? Journal of the American College of Cardiology, 41, 2197-2204.
29. Pedersen, O. D., Bagger, H., Kober, L., & Torp-Pedersen, C. (1999). Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation, 100, 376-380.
30. Li, D., Shinagawa, K., Pang, L., Leung, T. K., Cardin, S., Wang, Z., et al. (2001). Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation, 104, 2608-2616.
31. Nattel, S., & Li, D. (2000). Ionic remodelling in the heart: Pathophysiological significance and new therapeutic opportunities for atrial fibrillation. Circulation Research, 87, 440-447.
32. Madrid, A. H., Bueno, M. G., Rebollo, J. M. G., Marin, I., Pena, G., Bernal, E., et al. (2002). Use of Irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation. Circulation, 106, 331-336.
33. Madrid, A. H., Peng, J., Zamora, J., Marin, I., Bernal, E., Escobar, C., et al. (2004). The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: Meta-analysis of randomized controlled clinical trials. PACE, 27, 1405-1410.
34. Goldstein, R. N., Khrestian, C., Carlsson, L., & Waldo, A. L. (2004). Azd7009: A new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. Journal of Cardiovascular Electrophysiology, 1444-1450.
35. Persson, F., Carlsson, L., Duker, G., & Jacobson, I. (2005). Blocking characteristics of hERG, hNav1.5, and hKvLQT1/hminK after administration of the novel anti-arrhythmic compound AZD7009. Journal of Cardiovascular Electrophysiology, 16(3), 329-341.
36. Blaauw, Y., Gogelein, H., Tieleman, R. G., van Hunnik, A., Schotten, U., & Allessie, M. A. (2004). "Early" class III drugs for the treatment of atrial fibrillation: Efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation, 110, 1717-1724.
37. Roy, D., Rowe, B. H., Stiell, I. G., Coutu, B., Ip, J. H., Phaneuf, D., et al. CRAFT Investigators (2004). A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. Journal of the American College of Cardiology, 44, 2355-2361.
38. Gilmour, R. F., & Zipes, D. P. (2004). Mechanisms of disease: New mechanisms of antiarrhythmic actions. Natural Clinical Practice. Cardiovascular Medicine, 1, 37-41.
39. Satoh, T., & Zipes, D. P. (1996). Unequal atrial stretch in dogs increases dispersion of refractoriness conducive to developing atrial fibrillation. Journal of Cardiovascular Electrophysiology, 7, 833?842.
40. Bode, F., Sachs, F., & Franz, M. R. (2001). Tarantula peptide inhibits atrial fibrillation. Nature, 409, 35?36.
41. Yao, J.-A., Hussain, W., Patel, P., Peters, N. S., Boyden, P. A., Wit, A. L., et al. (2003). Remodeling of gap junction channel function in epicardial border zone of healing canine infarcts. Circulation Research, 92, 437?443.